Blueprint Medicines Corporation

Good morning, my name is Juan and I will be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicine's first quarter 2022 financial results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press start followed by number one on your telephone keypad. If you would like to withdraw your question, please press star followed by number two. Please plan to limit yourself to one question. Thank you. I would now like to turn the call over to your host, Gina Cohen from Blueprint Medicines. Gina, you may begin your conference.

Thank you, Juan. Good morning, everyone, and welcome to Blueprint Medicines' first quarter 2022 financial and operating results conference call. This morning, we issued a press release which outlines the topics we plan to discuss today. You can access the press release, as well as the slides that we'll be reviewing today, by going to the Investors section of our website at www.blueprintmedicines.com. Today on our call, Kate Haviland, our Chief Executive Officer, will discuss Blueprint Medicine's Pillars for Growth through 2023. Christy Rossi, our Chief Operating Officer, will provide an Advance SM launch update. Selena Lee, our chief commercial officer, will provide a non-advanced SM market opportunity update. Becker Hughes, chief medical officer, will review our recent clinical progress and highlight upcoming milestones across our growing portfolio. And Mike Lansdell, our chief financial officer, will review our first quarter 2022 financial results. Percy Carter, our chief scientific officer, is also joining our call and will be available for Q&A. Before we get started, I would like to remind everyone that statements we make on this conference call will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in the risk factor section of SEC filings. In addition, any forward-looking statement made on this call represents our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements. Now, here's our CEO, Kate Haviland.

Thank you, Jenna, and good morning, everyone. We appreciate you joining the call today. At Blueprint, we are clear in our goal to be the leading precision medicine company. Building on this quarter's success, the next 12 to 18 months will be unprecedented for us as we execute on multiple milestones, driving value creation across all aspects of our business. Blueprint has an incredibly unique profile with a diversity of significant growth drivers and a strong balance sheet that will enable us to outperform the sector over time as we expand global commercial execution. progress our clinical stage portfolio, and drive innovation through our leading precision medicine discovery platform. The first quarter of this year was marked by a number of important milestones across our business. We continued to solidify Avakit as the standard of care in advanced systemic mastocytosis, or SM, in the US, and we closed the quarter with the European Commission approval of Avakit in advanced SM. Our European launch is now underway. The global launch of Avakit and Advanced SM is building a strong real-world value proposition and an important foundation of relationships as we prepare for the top-line data from our registration-enabling pioneer trial and non-advanced SM late in the summer. Avakit has the potential to be the first and only treatment approved for non-advanced SM. With positive results from the Pioneer study, we will have developed a comprehensive body of clinical evidence demonstrating the remarkable efficacy and profound benefits to SM patients across the spectrum of disease, while also driving significant near-term growth for Blueprint. Another highlight from the first quarter were the data we presented at the AACR annual meeting across our EGFR and CDK2 franchises. It is early days for these programs, but there are many reasons for us to be encouraged about the differentiation of our investigational therapies and their prospects to address major medical needs and difficult to treat and prevalent cancers. As our strength this past quarter demonstrates, we are well on our way of delivering on the goals we have set for ourselves this year, while also building a foundation to drive value well beyond 2022. If you fast forward, for instance, to the end of 2023, We expect to be launching Avakit in non-Advanced SM, engaging regulatory authorities on registration plans for our EGFR and CDK2 development programs, and expanding our pipeline with new programs in areas of significant medical need. With that, let me turn the call over to Christy to discuss the progress we have made on the Avakit launch in Advanced SM. Christy?